Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02075047 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Terminated
- Registry status
- Phase 3
- Development phase
- 171
- Enrollment target
NCT02075047 is a Phase 3 study that was terminated before completion, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 171 participants.
The verdict
NCT02075047, a Phase 3 study, was terminated before completion, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 171 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed).
Interventions
- DRUG placebo oral capsules
- DRUG ziprasidone oral capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2014-05-23 |
| Est. Completion | 2020-05-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02075047
The ClinicalTrials.gov registry entry for NCT02075047 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo oral capsules is the first listed.
NCT02075047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02075047 about?
NCT02075047 is a clinical study titled "Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder". The purpose of this study is to determine if ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed).
What is the current status of trial NCT02075047?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 171 participants. The study started on 2014-05-23. Estimated completion is 2020-05-18.
What interventions are being tested in trial NCT02075047?
The interventions under investigation include: placebo oral capsules (DRUG), ziprasidone oral capsules (DRUG).
Who is sponsoring clinical trial NCT02075047?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.